| Bioactivity | MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19[1]. |
| Invitro | MMT5-14 (10 μM; 0-12 h) increases epithelial cell uptake[1].MMT5-14 (5 μM; 2 d) shows a better in vitro antiviral activity than remdesivir[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | MMT5-14 (10 mg/kg; i.v. once) shows a higher stability than remdesivir in microsomes, and shows higher concentrations of prodrugs and active metabolites (NTP) in blood and lungs[1]. Animal Model: |
| Name | MMT5-14 |
| CAS | 2719679-31-7 |
| Formula | C39H55N6O8P |
| Molar Mass | 766.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 7. |
MMT5-14
CAS: 2719679-31-7 F: C39H55N6O8P W: 766.86
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.